Children's Hospital Colorado, University of Colorado School of Medicine, Section of Allergy and Immunology, Aurora, Colorado.
Department of Pediatrics, University of Colorado School of Medicine, Adult and Child Consortium for Health Outcomes Research and Delivery Science (ACCORDS), Aurora, Colorado.
Ann Allergy Asthma Immunol. 2018 Nov;121(5):575-579. doi: 10.1016/j.anai.2018.06.018. Epub 2018 Jun 27.
Both oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT) are emerging potential treatments for peanut allergy. Caregiver goals and expectations of these therapies are poorly defined.
To determine caregiver goals and expectations of food allergy therapy.
Twenty-two detailed, semistructured interviews of OIT and EPIT caregivers were conducted, allowing caregivers to describe their motivations for and experiences with food allergy therapy and life with a peanut allergic child.
In this sample, caregivers of peanut allergic children enrolled in OIT or EPIT phase 3 trials expressed a primary goal for their child to develop a buffer against an unintentional peanut exposure. The perception of the buffer varied, representing a decreased reaction severity on exposure, increased time to react to allow for assessment, or increased threshold of peanut exposure tolerated. Although caregivers expressed that a buffer may increase their confidence in travel and dining outside the home, they do not anticipate this buffer would lessen their overall level of pretherapy anxiety, allergen-associated vigilance, or avoidance practices. Most of the caregivers hope the buffer will increase their and their child's perceived sense of freedom for the child's actions and social interactions, translating to quality of life improvement, while still respecting the limitations of having a severe allergy that has been partially treated. No caregiver viewed these therapies as a cure, and most viewed treatment as a supplement to their current avoidance practices.
Caregivers of peanut allergic children strongly desire that OIT and EPIT result in a buffer against an unintentional reaction, although most admitted that this would not significantly change their anxiety and family's current lifestyle.
口服免疫疗法（OIT）和经皮免疫疗法（EPIT）都是治疗花生过敏的新兴潜在疗法。这些疗法的护理人员目标和期望尚未明确。
确定食物过敏治疗的护理人员目标和期望。
对 22 名接受 OIT 和 EPIT 治疗的过敏症护理人员进行了详细的半结构式访谈，使护理人员能够描述他们对食物过敏治疗和有花生过敏儿童生活的动机和体验。
在该样本中，参加 OIT 或 EPIT 第三阶段试验的花生过敏儿童的护理人员表达了他们孩子的主要目标，即培养对意外花生暴露的缓冲能力。对缓冲能力的看法各不相同，代表暴露时反应严重程度降低、反应时间增加以进行评估，或耐受的花生暴露阈值增加。尽管护理人员表示，缓冲剂可能会增加他们对旅行和在家外就餐的信心，但他们预计这不会减轻他们总体上治疗前的焦虑、与过敏原相关的警惕性或回避行为。大多数护理人员希望缓冲剂能增加孩子的行动和社交互动的自由度，从而提高生活质量，同时仍尊重已部分治疗的严重过敏的局限性。没有护理人员将这些疗法视为治愈方法，大多数人认为治疗是对他们目前回避行为的补充。
花生过敏儿童的护理人员强烈希望 OIT 和 EPIT 能产生对意外反应的缓冲作用，尽管大多数人承认这不会显著改变他们的焦虑和家庭的当前生活方式。
